Stockreport

Sana: Major Inflection Point For SC291 In 2025 Targeting Lupus [Seeking Alpha]

Sana Biotechnology, Inc.  (SANA) 
PDF Terry Chrisomalis Investing Group Leader Follow Summary Sana Biotechnology results from the phase 1 study using SC291 for the treatment of patients with SLE are [Read more]